Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 654
- Registration Number
- NCT00343551
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
SPP100 Dose Finding Study in Japan
- Conditions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00311012
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction
- Conditions
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00299832
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Japan
SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
- Conditions
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00299806
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Japan
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
- Conditions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 976
- Registration Number
- NCT00294710
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 693
- Registration Number
- NCT00262236
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
- Conditions
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 641
- Registration Number
- NCT00260923
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 336
- Registration Number
- NCT00219102
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
🇺🇦Investigative Site, Kiev, Ukraine
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 355
- Registration Number
- NCT00219167
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1797
- Registration Number
- NCT00219180
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.